Immunological Mechanisms of Vaccine-Induced Protection against SARS-CoV-2 in Humans
Abstract
:1. Introduction
2. Sensing of SARS-CoV-2 Pathogen by Innate Immunity
3. Humoral and Cell Mediated Immune Responses against SARS-CoV-2
4. Vaccine-Induced Immune Responses against SARS-CoV-2 Infections
4.1. Nucleic Acid-Based Vaccines for COVID-19
4.1.1. Immunological Mechanisms of Different m-RNA Vaccine-Induced Protection against SARS-CoV-2RNAVaccines
4.1.2. Immunological Mechanisms of Different DNA Based Vaccine-Induced Protection against SARS-CoV-2
4.2. Immunological Mechanisms of Different Adenoviral Vector-Based Vaccines-Induced Protection against SARS-CoV-2
5. Vaccines and Its Role in Inducing Humoral Adaptive Immunity
6. Conclusions
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Conflicts of Interest
References
- Zeyaullah, M.; AlShahrani, A.M.; Muzammil, K.; Ahmad, I.; Alam, S.; Khan, W.H.; Ahmad, R. COVID-19 and SARS-CoV-2 Variants: Current Challenges and Health Concern. Front. Genet. 2021, 12, 693916. [Google Scholar] [CrossRef] [PubMed]
- WHO Coronavirus (COVID-19) Dashboard. Available online: https://covid19.who.int/ (accessed on 3 September 2021).
- Halstead, S.B.; Katzelnick, L. COVID-19 Vaccines: Should We Fear ADE? J. Infect. Dis. 2020, 222, 1946–1950. [Google Scholar] [CrossRef]
- Le, T.T.; Cramer, J.P.; Chen, R.; Mayhew, S. Evolution of the COVID-19 vaccine development landscape. Nat Rev Drug Discov. 2020, 19, 667–668. [Google Scholar] [CrossRef]
- Pronker, E.S.; Weenen, T.C.; Commandeur, H.; Claassen, E.H.; Osterhaus, A.D. Risk in vaccine research and development quantified. PLoS ONE 2013, 8, e57755. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Wang, B.; Godillot, A.P.; Madaio, M.P.; Weiner, D.B.; Williams, W.V. Vaccination against pathogenic cells by DNA inoculation. Curr. Top. Microbiol. Immunol. 1998, 226, 21–35. [Google Scholar] [PubMed]
- Davis, H.L.; Demeneix, B.A.; Quantin, B.; Coulombe, J.; Whalen, R.G. Plasmid DNA is superior to viral vectors for direct gene transfer into adult mouse skeletal muscle. Hum. Gene Ther. 1993, 4, 733–740. [Google Scholar] [CrossRef]
- Hurpin, C.; Rotarioa, C.; Bisceglia, H.; Chevalier, M.; Tartaglia, J.; Erdile, L. The mode of presentation and route of administration are critical for the induction of immune responses to p53 and antitumor immunity. Vaccine 1998, 16, 208–215. [Google Scholar] [CrossRef]
- Sadarangani, M.; Marchant, A.; Kollmann, T.R. Immunological mechanisms of vaccine-induced protection against COVID-19 in humans. Nat. Rev. Immunol. 2021, 21, 475–484. [Google Scholar] [CrossRef] [PubMed]
- The Adaptive Immune System. In Molecular Biology of the Cell, 4th ed.; Garland Science: New York, NY, USA, 2002. Available online: https://www.ncbi.nlm.nih.gov/books/NBK21070/ (accessed on 2 September 2021).
- Sette, A.; Crotty, S. Adaptive immunity to SARS-CoV-2 and COVID-19. Cell 2021, 184, 861–880. [Google Scholar] [CrossRef]
- Akira, S.; Uematsu, S.; Takeuchi, O. Pathogen recognition and innate immunity. Cell 2006, 124, 783–801. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Pulendran, B. Modulating vaccine responses with dendritic cells and Toll-like receptors. Immunol. Rev. 2004, 199, 227–250. [Google Scholar] [CrossRef]
- Loo, Y.M.; Fornek, J.; Crochet, N.; Bajwa, G.; Perwitasari, O.; Martinez-Sobrido, L.; Akira, S.; Gill, M.A.; García-Sastre, A.; Katze, M.G.; et al. Distinct RIG-I and MDA5 signaling by RNA viruses in innate immunity. J. Virol. 2008, 82, 335–345. [Google Scholar] [CrossRef] [Green Version]
- Takeshita, F.; Kobiyama, K.; Miyawaki, A.; Jounai, N.; Okuda, K. The non-canonical role of Atg family members as suppressors of innate antiviral immune signaling. Autophagy 2008, 4, 67–69. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Lei, X.; Dong, X.; Ma, R.; Wang, W.; Xiao, X.; Tian, Z.; Wang, C.; Wang, Y.; Li, L.; Ren, L.; et al. Activation and evasion of type I interferon responses by SARS-CoV-2. Nat. Commun. 2020, 11, 3810. [Google Scholar] [CrossRef]
- Young, B.E.; Fong, S.W.; Chan, Y.H.; Mak, T.M.; Ang, L.W.; Anderson, D.E.; Lee, C.Y.; Amrun, S.N.; Lee, B.; Goh, Y.S.; et al. Effects of a major deletion in the SARS-CoV-2 genome on the severity of infection and the inflammatory response: An observational cohort study. Lancet 2020, 396, 603–611. [Google Scholar] [CrossRef]
- Gudbjartsson, D.F.; Norddahl, G.L.; Melsted, P.; Gunnarsdottir, K.; Holm, H.; Eythorsson, E.; Arnthorsson, A.O.; Helgason, D.; Bjarnadottir, K.; Ingvarsson, R.F.; et al. Humoral Immune Response to SARS-CoV-2 in Iceland. N. Engl. J. Med. 2020, 383, 1724–1734. [Google Scholar] [CrossRef]
- Chen, G.; Wu, D.; Guo, W.; Cao, Y.; Huang, D.; Wang, H.; Wang, T.; Zhang, X.; Chen, H.; Yu, H.; et al. Clinical and immunological features of severe and moderate coronavirus disease 2019. J. Clin. Investig. 2020, 130, 2620–2629. [Google Scholar] [CrossRef] [Green Version]
- The Humoral Immune Response. In Immunobiology: The Immune System in Health and Disease, 5th ed.; Garland Science: New York, NY, USA, 2001. Available online: https://www.ncbi.nlm.nih.gov/books/NBK10752/ (accessed on 1 September 2021).
- Jordan, S.C. Innate and adaptive immune responses to SARS-CoV-2 in humans: Relevance to acquired immunity and vaccine responses. Clin. Exp. Immunol. 2021, 204, 310–320. [Google Scholar] [CrossRef]
- Stephens, D.S.; McElrath, M.J. COVID-19 and the Path to Immunity. JAMA 2020, 324, 1279–1281. [Google Scholar] [CrossRef] [PubMed]
- Suthar, M.S.; Zimmerman, M.G.; Kauffman, R.C.; Mantus, G.; Linderman, S.L.; Hudson, W.H.; Vanderheiden, A.; Nyhoff, L.; Davis, C.W.; Adekunle, O.; et al. Rapid Generation of Neutralizing Antibody Responses in COVID-19 Patients. Cell Rep. Med. 2020, 1, 100040. [Google Scholar] [CrossRef]
- Robbiani, D.F.; Gaebler, C.; Muecksch, F.; Lorenzi, J.; Wang, Z.; Cho, A.; Agudelo, M.; Barnes, C.O.; Gazumyan, A.; Finkin, S.; et al. Convergent antibody responses to SARS-CoV-2 in convalescent individuals. Nature 2020, 584, 437–442. [Google Scholar] [CrossRef]
- Dan, J.M.; Mateus, J.; Kato, Y.; Hastie, K.M.; Yu, E.D.; Faliti, C.E.; Grifoni, A.; Ramirez, S.I.; Haupt, S.; Frazier, A.; et al. Immunological memory to SARS-CoV-2 assessed for up to 8 months after infection. Science 2021, 371. [Google Scholar] [CrossRef]
- Rauch, S.; Jasny, E.; Schmidt, K.E.; Petsch, B. New Vaccine Technologies to Combat Outbreak Situations. Front. Immunol. 2018, 9, 1963. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Corr, M.; Lee, D.J.; Carson, D.A.; Tighe, H. Gene vaccination with naked plasmid DNA: Mechanism of CTL priming. J. Exp. Med. 1996, 184, 1555–1560. [Google Scholar] [CrossRef] [PubMed]
- Folegatti, P.M.; Ewer, K.J.; Aley, P.K.; Angus, B.; Becker, S.; Belij-Rammerstorfer, S.; Bellamy, D.; Bibi, S.; Bittaye, M.; Clutterbuck, E.A.; et al. Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: A preliminary report of a phase 1/2, single-blind, randomised controlled trial. Lancet 2020, 396, 467–478. [Google Scholar] [CrossRef]
- Porgador, A.; Irvine, K.R.; Iwasaki, A.; Barber, B.H.; Restifo, N.P.; Germain, R.N. Predominant role for directly transfected dendritic cells in antigen presentation to CD8+ T cells after gene gun immunization. J. Exp. Med. 1998, 188, 1075–1082. [Google Scholar] [CrossRef]
- Pardi, N.; Hogan, M.J.; Porter, F.W.; Weissman, D. mRNA vaccines—A new era in vaccinology. Nat. Rev. Drug Discov. 2018, 17, 261–279. [Google Scholar] [CrossRef] [Green Version]
- Bettini, E.; Locci, M. SARS-CoV-2 mRNA Vaccines: Immunological Mechanism and Beyond. Vaccines 2021, 9, 147. [Google Scholar] [CrossRef]
- Corbett, K.S.; Edwards, D.K.; Leist, S.R.; Abiona, O.M.; Boyoglu-Barnum, S.; Gillespie, R.A.; Himansu, S.; Schäfer, A.; Ziwawo, C.T.; DiPiazza, A.T.; et al. SARS-CoV-2 mRNA vaccine design enabled by prototype pathogen preparedness. Nature 2020, 586, 567–571. [Google Scholar] [CrossRef] [PubMed]
- Hobo, W.; Novobrantseva, T.I.; Fredrix, H.; Wong, J.; Milstein, S.; Epstein-Barash, H.; Liu, J.; Schaap, N.; van der Voort, R.; Dolstra, H. Improving dendritic cell vaccine immunogenicity by silencing PD-1 ligands using siRNA-lipid nanoparticles combined with antigen mRNA electroporation. Cancer Immunol. Immunother. 2013, 62, 285–297. [Google Scholar] [CrossRef]
- Wolff, J.A.; Malone, R.W.; Williams, P.; Chong, W.; Acsadi, G.; Jani, A.; Felgner, P.L. Direct gene transfer into mouse muscle in vivo. Science 1990, 247, 1465–1468. [Google Scholar] [CrossRef]
- Martinon, F.; Krishnan, S.; Lenzen, G.; Magné, R.; Gomard, E.; Guillet, J.G.; Lévy, J.P.; Meulien, P. Induction of virus-specific cytotoxic T lymphocytes in vivo by liposome-entrapped mRNA. Eur. J. Immunol. 1993, 23, 1719–1722. [Google Scholar] [CrossRef]
- Pollard, C.; De Koker, S.; Saelens, X.; Vanham, G.; Grooten, J. Challenges and advances towards the rational design of mRNA vaccines. Trends Mol. Med. 2013, 19, 705–713. [Google Scholar] [CrossRef] [PubMed]
- Lindsay, K.E.; Bhosle, S.M.; Zurla, C.; Beyersdorf, J.; Rogers, K.A.; Vanover, D.; Xiao, P.; Araínga, M.; Shirreff, L.M.; Pitard, B.; et al. Visualization of early events in mRNA vaccine delivery in non-human primates via PET-CT and near-infrared imaging. Nat. Biomed. Eng. 2019, 3, 371–380. [Google Scholar] [CrossRef]
- Pepini, T.; Pulichino, A.M.; Carsillo, T.; Carlson, A.L.; Sari-Sarraf, F.; Ramsauer, K.; Debasitis, J.C.; Maruggi, G.; Otten, G.R.; Geall, A.J.; et al. Induction of an IFN-Mediated Antiviral Response by a Self-Amplifying RNA Vaccine: Implications for Vaccine Design. J. Immunol. 2017, 198, 4012–4024. [Google Scholar] [CrossRef] [Green Version]
- Drugs and Lactation Database (LactMed) [Internet]. Bethesda (MD): National Library of Medicine (US); 2006-COVID-19 Vaccines. [Updated 2021 August 16]. Available online: https://www.ncbi.nlm.nih.gov/books/NBK565969/ (accessed on 4 September 2021).
- Baden, L.R.; El Sahly, H.M.; Essink, B.; Kotloff, K.; Frey, S.; Novak, R.; Diemert, D.; Spector, S.A.; Rouphael, N.; Creech, C.B.; et al. Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine. N. Engl. J. Med. 2021, 384, 403–416. [Google Scholar] [CrossRef] [PubMed]
- Huang, Q.; Zeng, J.; Yan, J. COVID-19 mRNA vaccines. J. Genet. Genom. 2021, 48, 107–114. [Google Scholar] [CrossRef] [PubMed]
- Silveira, M.M.; Moreira, G.; Mendonça, M. DNA vaccines against COVID-19: Perspectives and challenges. Life Sci. 2021, 267, 118919. [Google Scholar] [CrossRef] [PubMed]
- Comirnaty: COVID-19 mRNA Vaccine (Nucleoside-Modified). Available online: https://www.ema.europa.eu/en/medicines/human/EPAR/comirnaty (accessed on 3 September 2021).
- Comirnaty: CHMP Public Assessment Report. Available online: https://www.ema.europa.eu/en/documents/assessment-report/comirnaty-epar-public-assessment-report_en.pdf (accessed on 6 September 2021).
- Polack, F.P.; Thomas, S.J.; Kitchin, N.; Absalon, J.; Gurtman, A.; Lockhart, S.; Perez, J.L.; Pérez Marc, G.; Moreira, E.D.; Zerbini, C.; et al. C4591001 Clinical Trial Group. Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine. N. Engl. J. Med. 2020, 383, 2603–2615. [Google Scholar] [CrossRef]
- Walsh, E.E.; Frenck, R.W.; Falsey, A.R., Jr.; Kitchin, N.; Absalon, J.; Gurtman, A.; Lockhart, S.; Neuzil, K.; Mulligan, M.J.; Bailey, R.; et al. Safety and Immunogenicity of Two RNA-Based COVID-19 Vaccine Candidates. N. Engl. J. Med. 2020, 383, 2439–2450. [Google Scholar] [CrossRef]
- Borah, P.; Deb, P.K.; Al-Shar’i, N.A.; Dahabiyeh, L.A.; Venugopala, K.N.; Singh, V.; Shinu, P.; Hussain, S.; Deka, S.; Chandrasekaran, B.; et al. Perspectives on RNA Vaccine Candidates for COVID-19. Front. Mol. Biosci. 2021, 8, 635245. [Google Scholar] [CrossRef]
- Rauch, S.; Roth, N.; Schwendt, K.; Fotin-Mleczek, M.; Mueller, S.O.; Petsch, B. mRNA-based SARS-CoV-2 vaccine candidate CVnCoV induces high levels of virus-neutralising antibodies and mediates protection in rodents. NPJ Vaccines 2021, 6, 57. [Google Scholar] [CrossRef]
- Zhang, N.N.; Li, X.F.; Deng, Y.Q.; Zhao, H.; Huang, Y.J.; Yang, G.; Huang, W.J.; Gao, P.; Zhou, C.; Zhang, R.R.; et al. A Thermostable mRNA Vaccine against COVID-19. Cell 2020, 182, 1271–1283. [Google Scholar] [CrossRef]
- Rawat, K.; Kumari, P.; Saha, L. COVID-19 vaccine: A recent update in pipeline vaccines, their design and development strategies. Eur. J. Pharmacol. 2021, 892, 173751. [Google Scholar] [CrossRef]
- de Queiroz, N.; Marinho, F.V.; Chagas, M.A.; Leite, L.; Homan, E.J.; de Magalhães, M.; Oliveira, S.C. Vaccines for COVID-19: Perspectives from nucleic acid vaccines to BCG as delivery vector system. Microbes Infect. 2020, 22, 515–524. [Google Scholar] [CrossRef]
- Leitner, W.W.; Ying, H.; Restifo, N.P. DNA and RNA-based vaccines: Principles, progress and prospects. Vaccine 1999, 18, 765–777. [Google Scholar] [CrossRef] [Green Version]
- Tang, D.C.; DeVit, M.; Johnston, S.A. Genetic immunization is a simple method for eliciting an immune response. Nature 1992, 356, 152–154. [Google Scholar] [CrossRef] [PubMed]
- Liu, M.A. DNA vaccines: An historical perspective and view to the future. Immunol. Rev. 2011, 239, 62–84. [Google Scholar] [CrossRef]
- Schirmbeck, R.; Böhm, W.; Reimann, J. DNA vaccination primes MHC class I-restricted, simian virus 40 large tumor antigen-specific CTL in H-2d mice that reject syngeneic tumors. J. Immunol. 1996, 157, 3550–3558. [Google Scholar] [PubMed]
- Silveira, M.M.; Oliveira, T.L.; Schuch, R.A.; McBride, A.; Dellagostin, O.A.; Hartwig, D.D. DNA vaccines against leptospirosis: A literature review. Vaccine 2017, 35, 5559–5567. [Google Scholar] [CrossRef] [PubMed]
- Lee, L.; Izzard, L.; Hurt, A.C. A Review of DNA Vaccines Against Influenza. Front. Immunol. 2018, 9, 1568. [Google Scholar] [CrossRef] [Green Version]
- Coban, C.; Kobiyama, K.; Jounai, N.; Tozuka, M.; Ishii, K.J. DNA vaccines: A simple DNA sensing matter? Hum. Vaccines Immunother. 2013, 9, 2216–2221. [Google Scholar] [CrossRef] [Green Version]
- Hobernik, D.; Bros, M. DNA Vaccines-How Far From Clinical Use? Int. J. Mol. Sci. 2018, 19, 3605. [Google Scholar] [CrossRef] [Green Version]
- Smith, T.; Patel, A.; Ramos, S.; Elwood, D.; Zhu, X.; Yan, J.; Gary, E.N.; Walker, S.N.; Schultheis, K.; Purwar, M.; et al. Immunogenicity of a DNA vaccine candidate for COVID-19. Nat. Commun. 2020, 11, 2601. [Google Scholar] [CrossRef]
- Funk, C.D.; Laferrière, C.; Ardakani, A. A Snapshot of the Global Race for Vaccines Targeting SARS-CoV-2 and the COVID-19 Pandemic. Front. Pharmacol. 2020, 11, 937. [Google Scholar] [CrossRef] [PubMed]
- Seo, Y.B.; Suh, Y.S.; Ryu, J.I.; Jang, H.; Oh, H.; Koo, B.S.; Seo, S.H.; Hong, J.J.; Song, M.; Kim, S.J.; et al. Soluble Spike DNA Vaccine Provides Long-Term Protective Immunity against SARS-CoV-2 in Mice and Nonhuman Primates. Vaccines 2021, 9, 307. [Google Scholar] [CrossRef]
- Ramasamy, M.N.; Minassian, A.M.; Ewer, K.J.; Flaxman, A.L.; Folegatti, P.M.; Owens, D.R.; Voysey, M.; Aley, P.K.; Angus, B.; Babbage, G.; et al. Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): A single-blind, randomised, controlled, phase 2/3 trial. Lancet 2021, 396, 1979–1993. [Google Scholar] [CrossRef]
- Rayburn, E.R.; Zhang, R. Antisense, RNAi, and gene silencing strategies for therapy: Mission possible or impossible? Drug Discov. Today 2008, 13, 513–521. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Akita, H.; Kogure, K.; Moriguchi, R.; Nakamura, Y.; Higashi, T.; Nakamura, T.; Serada, S.; Fujimoto, M.; Naka, T.; Futaki, S.; et al. Nanoparticles for ex vivo siRNA delivery to dendritic cells for cancer vaccines: Programmed endosomal escape and dissociation. J. Control. Release Off. J. Control. Release Soc. 2010, 143, 311–317. [Google Scholar] [CrossRef] [PubMed]
- Piggott, J.M.; Sheahan, B.J.; Soden, D.M.; O’Sullivan, G.C.; Atkins, G.J. Electroporation of RNA stimulates immunity to an encoded reporter gene in mice. Mol. Med. Rep. 2009, 2, 753–756. [Google Scholar]
- Diken, M.; Kreiter, S.; Selmi, A.; Türeci, O.; Sahin, U. Antitumor vaccination with synthetic mRNA: Strategies for in vitro and in vivo preclinical studies. Methods Mol. Biol. 2013, 969, 235–246. [Google Scholar]
- Pollard, C.; Rejman, J.; De Haes, W.; Verrier, B.; Van Gulck, E.; Naessens, T.; De Smedt, S.; Bogaert, P.; Grooten, J.; Vanham, G.; et al. Type I IFN counteracts the induction of antigen-specific immune responses by lipid-based delivery of mRNA vaccines. Mol. Ther. J. Am. Soc. Gene Ther. 2013, 21, 251–259. [Google Scholar] [CrossRef] [Green Version]
- Weiss, R.; Scheiblhofer, S.; Roesler, E.; Weinberger, E.; Thalhamer, J. mRNA vaccination as a safe approach for specific protection from type I allergy. Expert Rev. Vaccines 2012, 11, 55–67. [Google Scholar] [CrossRef]
- Hoffmann, M.; Kleine-Weber, H.; Schroeder, S.; Krüger, N.; Herrler, T.; Erichsen, S.; Schiergens, T.S.; Herrler, G.; Wu, N.H.; Nitsche, A.; et al. SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell 2020, 181, 271–280. [Google Scholar] [CrossRef]
- Zang, R.; Gomez Castro, M.F.; McCune, B.T.; Zeng, Q.; Rothlauf, P.W.; Sonnek, N.M.; Liu, Z.; Brulois, K.F.; Wang, X.; Greenberg, H.B.; et al. TMPRSS2 and TMPRSS4 promote SARS-CoV-2 infection of human small intestinal enterocytes. Sci. Immunol. 2020, 5, 1–10. [Google Scholar] [CrossRef] [PubMed]
- Kalia, V.; Sarkar, S.; Gourley, T.S.; Rouse, B.T.; Ahmed, R. Differentiation of memory B and T cells. Curr. Opin. 2006, 18, 255–264. [Google Scholar] [CrossRef] [PubMed]
- Quan, F.S.; Huang, C.; Compans, R.W.; Kang, S.M. Virus-like particle vaccine induces protective immunity against homologous and heterologous strains of influenza virus. J. Virol. 2007, 81, 3514–3524. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Quan, F.S.; Compans, R.W.; Nguyen, H.H.; Kang, S.M. Induction of heterosubtypic immunity to influenza virus by intranasal immunization. J. Virol. 2008, 82, 1350–1359. [Google Scholar] [CrossRef] [Green Version]
- Crotty, S.; Aubert, R.D.; Glidewell, J.; Ahmed, R. Tracking human antigen-specific memory B cells: A sensitive and generalized ELISPOT system. J. Immunol. Methods 2004, 286, 111–122. [Google Scholar] [CrossRef] [PubMed]
- Rappuoli, R. Bridging the knowledge gaps in vaccine design. Nat. Biotechnol. 2007, 25, 1361–1366. [Google Scholar] [CrossRef]
- Sancho, D.; Gómez, M.; Sánchez-Madrid, F. CD69 is an immunoregulatory molecule induced following activation. Trends Immunol. 2005, 26, 136–140. [Google Scholar] [CrossRef] [PubMed]
- McHeyzer-Williams, L.J.; McHeyzer-Williams, M.G. Antigen-specific memory B cell development. Annu. Rev. Immunol. 2005, 23, 487–513. [Google Scholar] [CrossRef] [PubMed]
- Goel, H.; Gupta, I.; Mourya, M.; Gill, S.; Chopra, A.; Ranjan, A.; Rath, G.K.; Tanwar, P.A. systematic review of clinical and laboratory parameters of 3000 COVID-19 cases. Obstet. Gynecol. Sci. 2021, 64, 174–189. [Google Scholar] [CrossRef]
- Reif, K.; Ekland, E.H.; Ohl, L.; Nakano, H.; Lipp, M.; Förster, R.; Cyster, J.G. Balanced responsiveness to chemoattractants from adjacent zones determines B-cell position. Nature 2002, 416, 94–99. [Google Scholar] [CrossRef]
- Kelsoe, G. Studies of the humoral immune response. Immunol. Res. 2000, 22, 199–210. [Google Scholar] [CrossRef]
- Barnes, C.O.; Jette, C.A.; Abernathy, M.E.; Dam, K.A.; Esswein, S.R.; Gristick, H.B.; Malyutin, A.G.; Sharaf, N.G.; Huey-Tubman, K.E.; Lee, Y.E.; et al. SARS-CoV-2 neutralizing antibody structures inform therapeutic strategies. Nature 2020, 588, 682–687. [Google Scholar] [CrossRef]
- Goel, H.; Goyal, K.; Baranwal, P.; Dixit, A.; Upadhyay, T.K.; Upadhye, V.J. The Diagnostics Technologies and Control of COVID-19. Lett. Appl. NanoBioSci. 2021, 11, 3120–3133. [Google Scholar]
- Secchi, M.; Bazzigaluppi, E.; Brigatti, C.; Marzinotto, I.; Tresoldi, C.; Rovere-Querini, P.; Poli, A.; Castagna, A.; Scarlatti, G.; Zangrillo, A.; et al. COVID-19 survival associates with the immunoglobulin response to the SARS-CoV-2 spike receptor binding domain. J. Clin. Investig. 2020, 130, 6366–6378. [Google Scholar] [CrossRef]
Covishield | Covaxin | |
---|---|---|
DEVELOPED BY | Serum Institute of India | Bharat Biotech ICMR |
VACCINE TYPE | Non-Replicating Viral Vector | Inactivated |
EFFICACY | Drugs Controller General of India (DCGI): 70.42% overall | 60% |
STORAGE TEMPERATURE | 2–8 degree Celsius | 2–8 degree Celsius |
DOSES | Two Doses | Two Doses |
(0, 84 Days) | (0, 14 Days) |
Vaccine Developed by | Name of Vaccine | Mode | Type of Response |
---|---|---|---|
Pfizer/BioNtech | BNT162b2 | mRNA vaccine | IgG, IgA, CD8+ cells or CD4+ cells |
Moderna | mRNA-1273 | mRNA vaccine | CD8+ T cell |
CureVac AG | CVnCoV | mRNA vaccine | IL-6, IFN-α |
Abogen | ARCoV | mRNA vaccine | Th-1 biased |
Arcturus | ARCT-021 | mRNA vaccine | CD8+ cell-mediated and Th1/Th2-mediated immunity |
Symvivo | BacTRL-Spike | DNA vaccine | Induce both cellular and humoral immunity against spike protein |
Genexine | GX-19 | DNA vaccine | Th1-biased T cell responses, CD4+ and CD8+ T cell |
Inovio | INO-4800 | DNA vaccine | IgG cell |
AnGes Inc. and Osaka University | AG0301-COVID19 | DNA vaccine | Neutralizing antibodies and T-cell responses |
Inovio | GLS-5300 | DNA vaccine | T-cell responses, S1-ELISA |
Oxford/AstraZeneca | ChAdOx1 nCoV-19 | Adenoviral-vectored | Anti-IgA and IgG antibodies, T cell, Th1-biased T-cell, IFN-γ and IL-2, CD4+ T cells |
Gamaleya Research Institute | Gam-COVID-Vac (Sputnik V) | Adenoviral-vectored | IgG cell |
Johnson and Johnson | Janssen, Ad26.COV2.S | Adenoviral-vectored | Th1-biased, Th2-skewed, CD8+ T-cell, IFN-γ, IL-4, IL-5, or IL-10 |
Bharat Biotech | BBV152 | Whole cell inactivated viral vaccine | Th-1 cells, IgG cells |
Sinovac Biotech | SinoVec | Inactivated-virus COVID-19 Vaccine | T cells |
Beijing Bio-Institute of Biological Products Co Ltd. | Sinopharm | Inactivated-virus COVID-19 Vaccine | Neutralizing antibody GMT, Humoral responses |
CanSino Biologics Inc. | CanSino | Inactivated-virus COVID-19 vaccine | Specific ELISA antibody responses to the receptor binding domain (RBD) and neutralizing antibody responses |
Novavex | NVX-CoV2372 | Protein subunit vaccine | CD4+ T-cell, IgG cells |
Vektor State Research Center of Virology and Biotechnology in Russia | EpiVecCorona | Protein subunit vaccine | CD4+ T-cell |
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations. |
© 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Goyal, K.; Goel, H.; Baranwal, P.; Tewary, A.; Dixit, A.; Pandey, A.K.; Benjamin, M.; Tanwar, P.; Dey, A.; Khan, F.; et al. Immunological Mechanisms of Vaccine-Induced Protection against SARS-CoV-2 in Humans. Immuno 2021, 1, 442-456. https://doi.org/10.3390/immuno1040032
Goyal K, Goel H, Baranwal P, Tewary A, Dixit A, Pandey AK, Benjamin M, Tanwar P, Dey A, Khan F, et al. Immunological Mechanisms of Vaccine-Induced Protection against SARS-CoV-2 in Humans. Immuno. 2021; 1(4):442-456. https://doi.org/10.3390/immuno1040032
Chicago/Turabian StyleGoyal, Keshav, Harsh Goel, Pritika Baranwal, Anisha Tewary, Aman Dixit, Avanish Kumar Pandey, Mercilena Benjamin, Pranay Tanwar, Abhijit Dey, Fahad Khan, and et al. 2021. "Immunological Mechanisms of Vaccine-Induced Protection against SARS-CoV-2 in Humans" Immuno 1, no. 4: 442-456. https://doi.org/10.3390/immuno1040032